Opening Keynote: Realizing the Promise of Global Vaccines
Seth Berkley, IAVI

[Video: Part I, Part II, Part III ]
[Presentation Slides: Global Vaccines 202X_Berkley ]

In his plenary address, Dr. Seth Berkley, CEO of the International AIDS Vaccine Initiative, will discuss the need to strengthen the vaccine continuum- from development to delivery- to realize the full potential of vaccines over the next decade. From the perspective of a product developer who will soon be moving into leadership of a vaccine delivery partnership-the GAVI Alliance- Dr. Berkley will discuss the opportunities and challenges in linking vaccine development, delivery, and eradication efforts, and the critical role that financing, coordination, and emerging economies will play in ensuring that the goals of the Decade of Vaccines are achieved.

Introduction: Phil Johnson, Children’s Hospital of Philadelphia

[return to agenda]


IAVI website

The International AIDS Vaccine Initiative’s (IAVI) mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world.
More than 7,100 people a day are infected with HIV. An AIDS vaccine with 50% efficacy given to 30% of the population would avert 5.6 million new infections in low- and middle-income countries from 2015 to 2030.

Interview with Seth Berkley from Nature Medicine
Nature Med_Seth Berkley_April 2011 [download pdf]

Recent IAVI Media Releases
IAVI Announces Launch of Fellowship Program in AIDS Vaccine Research and Development
April 26, 2011

IAVI Responds to the News of Planned FEM-PrEP Trial Closure
April 18, 2011

40 Organizations Call for Delegates at UN High-Level Meeting to Intensify R&D Investments for New HIV-Prevention Methods
April 11, 2011


GAVI website

GAVI Issues Strategy Statement 0n Shaping Vaccine Markets
GAVI issued a statement on its strategy for 2011-2015 which “includes an explicit goal to shape vaccine markets,” noting that with its procurement partners it will achieve  this goal “through efficient procurement of quality vaccines while ensuring sustainable supply at affordable prices to GAVI countries.” GAVI-funded vaccines “now account for nearly half of the total value of UNICEF’s vaccine procurement, where UNICEF itself represents about 40% of the global volume of vaccine doses. These large volumes have helped promote the entry of vaccine manufacturers, particularly from emerging economies. Over the period 2000-2009, GAVI increased its supply base from eight manufacturers to 18 manufacturers in 2009, including 8 based in emerging markets.”

GAVI said that to move towards “a more active market management approach,” it is in the process of revising its supply and procurement strategy which will be reviewed by the GAVI Programme and Policy Committee in May 2011 and the GAVI Alliance Board in July 2011. GAVI also said it “recognizes the importance of timely, transparent and accurate information sharing on expected vaccine demand and supply dynamics. It therefore welcomes vaccine suppliers’ agreement to make pricing information more transparent. UNICEF publishes the vaccine prices paid to individual manufacturers. A few suppliers have not agreed at this stage to share their price information, but UNICEF hopes to add this information in the future.”

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: